Retension Pharmaceuticals, Inc. Common Stock (RTSN) FinancialsRTSNRetension Pharmaceuticals, Inc. Common Stock

In the context of the broader market, RTSN competes directly with industry leaders such as GNLX and LENZ. With a market capitalization of $91.37M, it holds a significant position in the sector. When comparing efficiency, RTSN's gross margin of N/A stands against GNLX's N/A and LENZ's 86.58%. Such benchmarking helps identify whether Retension Pharmaceuticals Inc. is trading at a premium or discount relative to its financial performance.

Retension Pharmaceuticals has shown consistent losses, with net income decreasing each quarter, culminating in a loss of $4,170,589 in Q2 2026. The current ratio is strong at 5.61, indicating good short-term liquidity, but the total equity has decreased significantly from $14,970,683 in Q1 2026 to $13,251,898 in Q2 2026, reflecting a deteriorating financial position.